Don’t miss a beat: Keep clicking for the latest news headlines and must-see videos
According to WPXI TV drug that treats Type 2 diabetes could become the best-selling medication in history if approved by the U.S. Food and Drug Administration to treat obesity.
The drug, tirzepatide, was created by Eli Lilly and approved as a diabetes treatment last year. While studying the drug as a treatment for diabetes, researchers also found it showed impressive results in clinical trials for weight loss.
The clinical trial showed that a higher dose of the drug reduced appetite and improved the body’s ability to break down sugar and fat, leading to a 22.5% loss in body weight for patients in the study. The average weight loss for those in the study was 52 pounds. [FULLSTORY]
Stay up to date: Click here for more news and videos
Healthline reports FDA officials were apparently encouraged by the results and gave the medication, which is sold by Eli Lilly & Co. under the brand name Mounjaro, the fast-track designation to be reviewed for treating obesity.
Eli Lilly officials said the company will use the data from the original trial and from the ongoing trial to gauge the effectiveness of tirzepatide in people with type 2 diabetes who also have excess weight or are living with obesity.
The second trial is expected to be finished in April 2023, although the FDA’s fast-track designationTrusted Source allows for the rolling submission of trial data. That means the FDA can review data as it comes in instead of waiting for the trial’s conclusion.
That expedites the review, possibly meaning a sooner approval date. The FDA grants fast-track designations for medications that can fill a serious unmet medical need.
Stay up to date: Click here for more news and videos
Important Note: This article is for informational purposes only and should not be taken as medical advice. If you are considering using any weight loss drug, it is essential to consult with a licensed healthcare professional first to determine if it is safe and appropriate for you.
Discover more from Your Assignment Editor
Subscribe to get the latest posts sent to your email.
